跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
REBINYN
Authorized
STANDARD
REBINYN
Novo Nordisk Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
e443ab823cd23e5e
Company
Novo Nordisk Canada Inc
Type
Standard
Approval Details
Approval Id
e443ab823cd23e5e
Drug Approval Canada Name
REBINYN
Product Name
REBINYN
Status
Marketed
Status Date
2024-02-13
Original Market Date
2024-02-13
Din
02532964
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Schedule D
Ahfs
20:28.16
Atc Original
B02BD04 COAGULATION FACTOR IX
Atc Name
b 02 bd 04
Aig Number
0159770004
Company Name
Novo Nordisk Canada Inc
Company Address
101-2476 Argentia Road, Mississauga, Ontario, Canada, L5N 6M1
Active Ingredients
COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED
3000 UNIT / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
e443ab823cd23e5e
Type
Standard
Back to Health Canada Approvals
REBINYN - Health Canada Drug Approval Details